Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.
Columnist Marisa Zeppieri welcomes the season of holiday food while offering tips to get people with lupus through any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback